Oncolytic Peptide LTX-315 Targets PD-L1 to Boost Anti-Tumor Immunity in Cancer
The oncolytic peptide LTX-315 targets PD-L1 on cancer cells to improve anti-tumor immune response, combining direct tumor killing with immune checkpoint modulation in a single molecule.
Quick Facts
What This Study Found
LTX-315 targets PD-L1 on cancer cells, combining direct oncolytic (membrane-disrupting) activity with immune checkpoint modulation for dual anti-tumor mechanism.
Key Numbers
How They Did This
In vitro and in vivo evaluation of LTX-315 PD-L1 targeting, oncolytic activity, and anti-tumor immune response modulation.
Why This Research Matters
Combining tumor killing with immune checkpoint modulation in a single peptide could eliminate the need for costly antibody-drug combinations.
The Bigger Picture
A peptide that kills tumors AND unmasks them to the immune system represents the ideal single-molecule cancer immunotherapy.
What This Study Doesn't Tell Us
Preclinical. PD-L1 targeting mechanism needs fuller characterization. Clinical development status uncertain.
Questions This Raises
- ?Would LTX-315 synergize with anti-PD-1 antibodies?
- ?Could it be combined with anti-CTLA-4 for broader immune activation?
- ?What is LTX-315's clinical development status?
Trust & Context
- Key Stat:
- Kill + unmask LTX-315 both kills cancer cells and removes their PD-L1 immune shield — combining two therapeutic functions in a single peptide
- Evidence Grade:
- Preclinical study with dual mechanism characterization.
- Study Age:
- Published in 2025.
- Original Title:
- Oncolytic peptide LTX-315 targets PD-L1 to improve antitumor immune response of nanosecond pulse electric field in liver cancer.
- Published In:
- Journal for immunotherapy of cancer, 14(1) (2026)
- Authors:
- Ji, Kun, Jing, Li, Xu, Tiantian, Cao, Shoujin, Zhang, Cong, Wang, Zilin, Zhou, Guanhui, Cao, Yunbo, Niu, Jiahua, Yang, Yuning, Chen, Xinhua, Ai, Jing, Sun, Jun-Hui, Xiong, Bin
- Database ID:
- RPEP-15379
Evidence Hierarchy
Frequently Asked Questions
How does one peptide fight cancer two ways?
LTX-315 physically destroys cancer cell membranes (direct killing) AND removes PD-L1 (the protein cancers use to hide from the immune system), allowing immune cells to recognize and attack the tumor.
Is this like a checkpoint inhibitor?
It combines checkpoint inhibition with direct tumor killing in a single small peptide — potentially simpler and cheaper than combining separate antibody drugs.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15379APA
Ji, Kun; Jing, Li; Xu, Tiantian; Cao, Shoujin; Zhang, Cong; Wang, Zilin; Zhou, Guanhui; Cao, Yunbo; Niu, Jiahua; Yang, Yuning; Chen, Xinhua; Ai, Jing; Sun, Jun-Hui; Xiong, Bin. (2026). Oncolytic peptide LTX-315 targets PD-L1 to improve antitumor immune response of nanosecond pulse electric field in liver cancer.. Journal for immunotherapy of cancer, 14(1). https://doi.org/10.1136/jitc-2025-012438
MLA
Ji, Kun, et al. "Oncolytic peptide LTX-315 targets PD-L1 to improve antitumor immune response of nanosecond pulse electric field in liver cancer.." Journal for immunotherapy of cancer, 2026. https://doi.org/10.1136/jitc-2025-012438
RethinkPeptides
RethinkPeptides Research Database. "Oncolytic peptide LTX-315 targets PD-L1 to improve antitumor..." RPEP-15379. Retrieved from https://rethinkpeptides.com/research/ji-2026-oncolytic-peptide-ltx315-targets
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.